Publications

Steve Finkbeiner, MD, PhDArrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004 Oct 14; 431(7010):805-10. View in: PubMed
Steve Finkbeiner, MD, PhDSplice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression. View in: PubMed
Steve Finkbeiner, MD, PhDBrooks E, Arrasate M, Cheung K, Finkbeiner SM. Using antibodies to analyze polyglutamine stretches. Methods Mol Biol. 2004; 277:103-28. View in: PubMed
Steve Finkbeiner, MD, PhDCrystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches. View in: PubMed
Steve Finkbeiner, MD, PhDRao VR, Finkbeiner S. Secrets of a secretase: N-cadherin proteolysis regulates CBP function. Cell. 2003 Sep 5; 114(5):533-5. View in: PubMed
Steve Finkbeiner, MD, PhDAutomated microscope system for determining factors that predict neuronal fate. View in: PubMed
Steve Finkbeiner, MD, PhDBradley J, Finkbeiner S. An evaluation of specificity in activity-dependent gene expression in neurons. Prog Neurobiol. 2002 Aug; 67(6):469-77. View in: PubMed
Steve Finkbeiner, MD, PhDInclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. View in: PubMed
Steve Finkbeiner, MD, PhDHumbert S, Bryson EA, Cordelières FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002 Jun; 2(6):831-7. View in: PubMed
Steve Finkbeiner, MD, PhDUsing antibodies to analyze polyglutamine stretches. View in: PubMed